Skip to main content
Erschienen in:

17.06.2022 | Brief Communication

Surveillance mammography after treatment for male breast cancer

verfasst von: Siddhartha Yadav, Lindsey Sangaralingham, Stephanie R. Payne, Karthik V. Giridhar, Tina J. Hieken, Judy C. Boughey, Robert W. Mutter, John R. Hawse, Rafael E. Jimenez, Rachel A. Freedman, Sadia Khanani, Fergus J. Couch, Celine Vachon, Nilay Shah, Roberto A. Leon-Ferre, Kathryn J. Ruddy

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 3/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To identify the practice patterns related to use of surveillance mammography in male breast cancer (MaBC) survivors.

Methods

Using administrative claims data from OptumLabs Data Warehouse, we identified men who underwent surgery for breast cancer during 2007–2017. We calculated the proportion of men who had at least one mammogram (a) within 13 months for all patients and (b) within 24 months amongst those who maintained their insurance coverage for at least that length of time after surgery. Multivariate logistic regression modeling was used to identify factors associated with mammography within each timeframe.

Results

Out of 729 total MaBC survivors, 209 (29%) underwent mammography within 13 months after surgery. Among those who had lumpectomy, 41% underwent mammography, whereas among those who had mastectomy, 27% had mammography. Amongst 526 men who maintained consistent insurance coverage for 24 months after surgery, 215 (41%) underwent mammography at least once during that 24-month period. In this cohort, the proportion who had at least one mammogram during the 24-month period was 49% after lumpectomy and 40% after mastectomy. In a multivariate logistic regression model, more recent diagnosis (2015+) and older age at diagnosis were associated with lower odds of undergoing mammography, while receipt of radiation was associated with higher odds of undergoing mammography.

Conclusions

Although recent ASCO guidelines recommend surveillance mammography after lumpectomy, a minority of MaBC survivors undergo surveillance mammography, even after lumpectomy. This is likely due to the paucity of data regarding the true benefits and harms of surveillance/screening mammography for MaBC.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Siegel RL, Miller KD, Jemal A (2019) Cancer statistics, 2019. CA Cancer J Clin 69:7–34CrossRef Siegel RL, Miller KD, Jemal A (2019) Cancer statistics, 2019. CA Cancer J Clin 69:7–34CrossRef
2.
Zurück zum Zitat Leon-Ferre RA, Giridhar KV, Hieken TJ et al (2018) A contemporary review of male breast cancer: current evidence and unanswered questions. Cancer Metastasis Rev 37:599–614CrossRef Leon-Ferre RA, Giridhar KV, Hieken TJ et al (2018) A contemporary review of male breast cancer: current evidence and unanswered questions. Cancer Metastasis Rev 37:599–614CrossRef
3.
Zurück zum Zitat National Comprehensive Cancer Network (2020) NCCN clinical practice guidelines in oncology. Breast Cancer Version 3.2019 National Comprehensive Cancer Network (2020) NCCN clinical practice guidelines in oncology. Breast Cancer Version 3.2019
4.
Zurück zum Zitat Hassett MJ, Somerfield MR, Baker ER et al (2020) Management of male breast cancer: ASCO guideline. J Clin Oncol 38(16):1849–1863CrossRef Hassett MJ, Somerfield MR, Baker ER et al (2020) Management of male breast cancer: ASCO guideline. J Clin Oncol 38(16):1849–1863CrossRef
5.
Zurück zum Zitat Wallace PJ, Shah ND, Dennen T et al (2014) Optum Labs: building a novel node in the learning health care system. Health Aff (Millwood) 33:1187–1194CrossRef Wallace PJ, Shah ND, Dennen T et al (2014) Optum Labs: building a novel node in the learning health care system. Health Aff (Millwood) 33:1187–1194CrossRef
6.
Zurück zum Zitat Ruddy KJ, Sangaralingham L, Freedman RA et al (2018) Adherence to guidelines for breast surveillance in breast cancer survivors. J Natl Compr Canc Netw 16:526–534CrossRef Ruddy KJ, Sangaralingham L, Freedman RA et al (2018) Adherence to guidelines for breast surveillance in breast cancer survivors. J Natl Compr Canc Netw 16:526–534CrossRef
7.
Zurück zum Zitat Auvinen A, Curtis RE, Ron E (2002) Risk of subsequent cancer following breast cancer in men. J Natl Cancer Inst 94:1330–1332CrossRef Auvinen A, Curtis RE, Ron E (2002) Risk of subsequent cancer following breast cancer in men. J Natl Cancer Inst 94:1330–1332CrossRef
8.
Zurück zum Zitat Satram-Hoang S, Ziogas A, Anton-Culver H (2007) Risk of second primary cancer in men with breast cancer. Breast Cancer Res 9:R10CrossRef Satram-Hoang S, Ziogas A, Anton-Culver H (2007) Risk of second primary cancer in men with breast cancer. Breast Cancer Res 9:R10CrossRef
9.
Zurück zum Zitat Ferzoco RM, Ruddy KJ (2015) Optimal delivery of male breast cancer follow-up care: improving outcomes. Breast Cancer (Dove Med Press) 7:371–379 Ferzoco RM, Ruddy KJ (2015) Optimal delivery of male breast cancer follow-up care: improving outcomes. Breast Cancer (Dove Med Press) 7:371–379
10.
Zurück zum Zitat Pritzlaff M, Summerour P, McFarland R et al (2017) Male breast cancer in a multi-gene panel testing cohort: insights and unexpected results. Breast Cancer Res Treat 161:575–586CrossRef Pritzlaff M, Summerour P, McFarland R et al (2017) Male breast cancer in a multi-gene panel testing cohort: insights and unexpected results. Breast Cancer Res Treat 161:575–586CrossRef
11.
Zurück zum Zitat Wang YA, Jian J-W, Hung C-F et al (2018) Germline breast cancer susceptibility gene mutations and breast cancer outcomes. BMC Cancer 18:315CrossRef Wang YA, Jian J-W, Hung C-F et al (2018) Germline breast cancer susceptibility gene mutations and breast cancer outcomes. BMC Cancer 18:315CrossRef
12.
Zurück zum Zitat Dong C, Hemminki K (2001) Second primary breast cancer in men. Breast Cancer Res Treat 66:171–172CrossRef Dong C, Hemminki K (2001) Second primary breast cancer in men. Breast Cancer Res Treat 66:171–172CrossRef
Metadaten
Titel
Surveillance mammography after treatment for male breast cancer
verfasst von
Siddhartha Yadav
Lindsey Sangaralingham
Stephanie R. Payne
Karthik V. Giridhar
Tina J. Hieken
Judy C. Boughey
Robert W. Mutter
John R. Hawse
Rafael E. Jimenez
Rachel A. Freedman
Sadia Khanani
Fergus J. Couch
Celine Vachon
Nilay Shah
Roberto A. Leon-Ferre
Kathryn J. Ruddy
Publikationsdatum
17.06.2022
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 3/2022
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-022-06645-w

Neu im Fachgebiet Onkologie

CDK4/6-Inhibitoren bei Brustkrebs in die Zweitlinie aufschieben?

Ergebnisse einer Phase-III-Studie sprechen dafür, dass die Behandlung mit CDK4/6-Inhibitoren bei fortgeschrittenem HR-positivem, HER2-negativem Brustkrebs auch auf die Zweitlinie verschoben werden könnte, ohne die onkologischen Ergebnisse zu kompromittieren.

Cannabisextrakt verbessert Antiemese bei Chemotherapie

Sprechen Krebskranke auf die übliche Antiemese während einer Chemotherapie nicht ausreichend an, lohnt sich möglicherweise eine Behandlung mit Cannabisextrakt. In einer Phase-2/3-Studie ließ sich die antiemetische Response mit einem solchen Extrakt erheblich verbessern.

Veränderung der Brustdichte beeinflusst das Krebsrisiko

Die radiologische Dichte des Mammagewebes ist mit dem Risiko assoziiert, an Brustkrebs zu erkranken. Dabei wirken sich laut Ergebnissen einer Studie auch Dichteänderungen aus. Fünf Verlaufsmuster lassen sich dabei unterscheiden.

PMBCL mit CMR: Radiatio kann ohne Risiko weggelassen werden

Patienten mit primär mediastinalem B-Zell-Lymphom (PMBCL), die nach der Induktionstherapie eine komplette metabolische Remission (CMR) erreichen und keine konsolidierende Bestrahlung erhalten, müssen offenbar keine Überlebensnachteile fürchten.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.